3-Pyrazin-2-yl-propionic acid ethyl ester | 579475-94-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-Pyrazin-2-yl-propionic acid ethyl ester
• 英文别名: ethyl 3-pyrazin-2-ylpropanoate
• CAS: 579475-94-8
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: ZKVXJLJUXNGCGH-UHFFFAOYSA-N

物化性质

• 沸点：
  263.8±25.0 °C(Predicted)
• 密度：
  1.114±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-甲基吡嗪 、 溴乙酸叔丁酯 在 正丁基锂 、 sodium ethanolate 、 二异丙胺 作用下， 以 四氢呋喃 、 乙醇 、 hexane-2560 mL 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 生成 3-Pyrazin-2-yl-propionic acid ethyl ester
  参考文献：
  名称：

  Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss

  摘要：

  本发明涉及治疗患有耳鸣、听力丧失或耳鸣和听力丧失的方法，包括向受试者单独或与选择性5-羟色胺再摄取抑制剂的有效量结合，给予有效量的NK1受体拮抗剂。同时还提供了组合物和药物配方。

  公开号：

  US20100317666A1

文献信息

• [EN] PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE LA PIPERIDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003066635A1

  公开（公告）日：2003-08-14

  The present invention relates to piperidine derivatives of formula (I): R represents halogen or C1-4 alkyl; R1 represents C1-4 alkyl; R2 or R3 independently represent hydrogen or C1-4 alkyl; R4 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen; R5 represents hydrogen , C1-4 alkyl or C3-7 cycloalkyl; R6 is hydrogen and R7 is a radical of formula (W): R6 is a radical of formula (W) and R7 is hydrogen; X represents CH2, NR5 or O; Y represents Nitrogen and Z is CH or Y represents CH and Z is Nitrogen; A represents C(O) or S(O)q, provided that when Y is nitrogen and Z is CH, A is not S(O)q; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p and q are independently an integer from 1 to 2; and pharmaceutically acceptable salts and solvates thereof. The process for their preparation and their use in the treatment of condition mediated by tachykinins.

  本发明涉及式(I)的哌啶衍生物： R代表卤素或C1-4烷基；R1代表C1-4烷基；R2或R3独立地代表氢或C1-4烷基；R4代表三氟甲基、C1-4烷基、C1-4烷氧基、三氟甲氧基或卤素；R5代表氢、C1-4烷基或C3-7环烷基；R6为氢，R7为式(W)的基团：R6为式(W)的基团，R7为氢；X代表CH2、NR5或O；Y代表氮，Z为CH，或者Y代表CH，Z为氮；A代表C(O)或S(O)q，但当Y为氮，Z为CH时，A不是S(O)q；m为零或1到3的整数；n为1到3的整数；p和q独立地为1到2的整数；以及其药学上可接受的盐和溶剂化物。其制备方法及其在由Tachykinins介导的疾病治疗��的应用。
• Piperidine derivatives
  申请人：Alvaro Giuseppe

  公开号：US20050176715A1

  公开（公告）日：2005-08-11

  The present invention relates to piperidine derivatives of formula (I): R represents halogen or C 1-4 alkyl R 1 represents C 1-4 alkyl; R 2 or R 3 independently represent hydrogen or C 1-4 alkyl; R 4 represents trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy or halogen; R 5 represents hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; R 6 is hydrogen and R 7 is a radical of formula (W): or R 6 is a radical of formula (W) and R 7 is hydrogen; X represents CH 2 , NR 5 or O; Y represents Nitrogen and Z is CH or Y represents CH and Z is Nitrogen; A represents C(O) or S(O)q, provided that when Y is nitrogen and Z is CH, A is not S(O) q ; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p and q are independently an integer from 1 to 2; and pharmaceutically acceptable salts and solvates thereof. The process for their preparation and their use in the treatment of a condition mediated by tachykinins.

  本发明涉及式（I）的哌啶衍生物：其中，R代表卤素或C1-4烷基，R1代表C1-4烷基，R2或R3独立地代表氢或C1-4烷基，R4代表三氟甲基、C1-4烷基、C1-4烷氧基、三氟甲氧基或卤素，R5代表氢、C1-4烷基或C3-7环烷基，R6为氢，R7为式（W）的基团；或者R6为式（W）的基团，R7为氢；X代表CH2、NR5或O；Y代表氮，Z为CH或Y代表CH，Z为氮；A代表C（O）或S（O）q，但当Y为氮且Z为CH时，A不是S（O）q；m为零或1至3的整数；n为1至3的整数；p和q独立地为1至2的整数；以及其药学上可接受的盐和溶剂化物。其制备过程及其在治疗由速激肽介导的疾病中的应用。
• PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS
  申请人：Alvaro Giuseppe

  公开号：US20090326032A1

  公开（公告）日：2009-12-31

  The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I) wherein R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkylC 1-6 alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; R 3 is C 1-6 alkyl, C 1-6 haloalkyl, C 1-3 alkoxyC 1-3 alkyl or C 1-3 haloalkoxyC 1-3 alkyl; or R 1 and R 3 , together with the interconnecting atoms, form a saturated or unsaturated 4- to 6-membered ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R 4 is independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; q is 1 or 2; either R 5 or R 6 is —O—R 7 or —OCH 2 R 7 , wherein the other R 5 or R 6 is hydrogen or R 4 ; and wherein R 7 is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; or a pharmaceutically acceptable salt or solvate thereof; as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders.

  本发明涉及一种含有NK1受体拮抗剂和公式（I）的钠通道阻滞剂化合物的制药组合物，其中R1和R2独立地是氢、C1-6烷基或C3-6环烷基C1-6烷基；或者R1和R2与它们连接的氮一起可以形成未取代的3、4、5或6元饱和环；R3是C1-6烷基、C1-6卤代烷基、C1-3烷氧基C1-3烷基或C1-3卤代烷氧基C1-3烷基；或者R1和R3与连接的原子一起形成一个饱和或不饱和的4-至6元环；X是碳或氮；n为0、1或2，其中当存在时，每个R4是从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中独立选择的；q为1或2；R5或R6为—O—R7或—OCH2R7，其中另一个R5或R6是氢或R4；其中R7为苯环或5-或6-元芳香杂环环（独立地包含一个或多个氮、硫或氧原子），其中苯环或杂环环可以选择地被一个或多个从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中独立选择的基团取代；或其药学上可接受的盐或溶剂；作为同时或顺序给药的联合制剂，并且在治疗某些疾病，包括癫痫和情绪障碍中使用这种组合物。
• Piperidine Derivatives
  申请人：Alvaro Giuseppe

  公开号：US20070099914A1

  公开（公告）日：2007-05-03

  The present invention relates to methods for treatment of inflammatory diseases of the bladder.

  本发明涉及治疗膀胱炎症性疾病的方法。
• PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1
  申请人：Alvaro Giuseppe

  公开号：US20100105688A1

  公开（公告）日：2010-04-29

  The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker, wherein at least one of them is at subtherapeutic dose, as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.

  本发明涉及一种制药组合物，包括NK1受体拮抗剂和钠通道阻滞剂，其中至少一种剂量为亚治疗剂量，作为同时或顺序给药的联合制剂，并且本发明还涉及在治疗某些疾病，包括癫痫、情绪障碍和疼痛方面使用这种组合物的方法。